Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sachdev Amit						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									5. Relationship of Reportin (Check all applicable) Director X Officer (give title			10% Ov	wner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 02/01/2022									below) below) EVP, Chief Patient Officer				
(Street) BOSTON MA 02210					4. If Amendment, Date of Original Filed (Month/Day/Year)									Lin	e) X Form Form				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Da				Date	Date		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)						d Securi Benefi Owned	ties cially I Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A (D) or)	Price	Transa	ction(s)			(111501. 4)
Common Stock				02/01/2022					A		9,800(1)		A	\$0.0	0 4	1,728		D	
Common Stock				02/01/2022				A		11,628(2)		A	\$0.0	0 5	53,356		D		
Common Stock				02/01/2022				A		8,210(3)		A	\$0.0	0 6	61,566		D		
Common Stock																882		I	401(k)
Common Stock															1	15,573		1 1	Held in Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
	n Date	e Execution Date, onth/Day/Year) if any		on Date,	4. Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Da (Month/Day/Y		tte ear)	Amour or Number of		str. unt ber	Derivative Security	derivative Securities Beneficially Owned Following Reported	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	(FRIEX PH. PORATED THERN A N M (S Security (In Stock Stock Stock Stock Stock Stock Derivative of Derivative	(First) RTEX PHARM PORATED THERN AVEN N MA (State) Security (Instr. 3) Stock Stock Stock Stock Stock Stock Stock Or Exercise Price of Derivative	(First) (N RTEX PHARMACEUTICA PORATED THERN AVENUE N MA 0: (State) (Z Table Security (Instr. 3) Stock Stock Stock Stock Stock Stock Stock Stock Conversion or Exercise Price of Derivative Price of Derivative	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE N MA 02210 (State) (Zip) Table I - Note Security (Instr. 3) Stock St	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE N MA 02210 (State) (Zip) Table I - Non-Deriva Security (Instr. 3) 2. Transact Date (Month/Date (Month/Date) Stock 02/01/2 Stock 02/01/2 Stock 102/01/2 Stock 102/01/2	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Security (Instr. 3) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock 02/01/2022 Stock Table II - Derivative Security Stock Table II - Derivative Security Stock Stock 3. Data (Nonth/Day/Year) 4. If And Date (Month/Day/Year)	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Security (Instr. 3) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock Table II - Derivative Security (e.g., puts, calls, value) Conversion or Exercise Price of Derivative Security (Month/Day/Year) Conversion or Exercise Price of Derivative Security (Month/Day/Year) RMA [VI 3. Date of E 02/01/2022 4. If Amend 2. Transaction Date (e.g., puts, calls, value) Execution Date (Month/Day/Year) A. Deemed Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8)	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Securities Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock Stock 02/01/2022 Stock 1. Transaction Date (Month/Day/Year) Stock 1. Table II - Derivative Securities (e.g., puts, calls, warrance) (e.g., puts, calls, warrance) (e.g., puts, calls, warrance) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrance) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrance) (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrance) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Securities Acque (Month/Day/Year) Stock Table II - Derivative Securities Acque (e.g., puts, calls, warrants, and core Execution Date (Month/Day/Year) Table II - Derivative Securities Acque (e.g., puts, calls, warrants, (Month/Day/Year) A. If Amendment, Date of Earliest Trans 02/01/2022 2. Transaction Date (Month/Day/Year) Stock Table II - Derivative Securities Acque (e.g., puts, calls, warrants, (Month/Day/Year) 2. Conversion or Exercise (Month/Day/Year) Price of Derivative Securities Acque (Month/Day/Year) 3. Transaction Date (Instr. Securities Acque (e.g., puts, calls, warrants, (A) or Disposed of (D) (Instr. 3, 4 and 5) In the Mark (Mark (Instr. Securities) (Month/Day/Year) A. Deemed Execution Date, if any (Month/Day/Year) In the Mark (Instr. Securities) (Month/Day/Year) A. Deemed Execution Date, if any (Month/Day/Year) In the Mark (Instr. Securities) (Month/Day/Year)	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Securities Acquired, Month/Day/Year) Security (Instr. 3) Table I - Non-Derivative Securities Acquired, Month/Day/Year) Security (Instr. 3) Table I - Non-Derivative Securities Acquired, Month/Day/Year) Security (Instr. 3) Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) Stock Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Date	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Securities Acquired, Disportative Stock Stock 12. Transaction [Month/Day/Year] [Indignated by the complete of the com	(First) (Middle) RTEX PHARMACEUTICALS PORATED THERN AVENUE Table I - Non-Derivative Securities Acquired, Disposed of, Code (nstr. of Exercise of Exercise of Execution Date of Conversion of Exercise of Execution Date of Conversion Conversion of Exercise of Execution Date of Conversion of Exercise of Execution Date of Original Filed (Month/Day/Year) MA	(First) (Middle) RTEX PHARMACEUTICALS OPACITED THERN AVENUE Table I - Non-Derivative Securities Acquired, Disposed of, or Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock 02/01/2022 A 11,628(2) Stock 12. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or (Code v Amount (A Day A Day Day A Day A Day A Day A Day A Day A Day Day	(First) (Middle) RTEX PHARMACEUTICALS ODATED THERN AVENUE Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock 02/01/2022 A 9,800(1) A Stock 02/01/2022 A 9,800(1) A Stock 02/01/2022 A 9,800(1) A Stock 11,628(2) A Stock Stock 12. Derivative Securities Acquired (Disposed of (D) (Instr. 3) Code V Amount (A) or (D) or (D	(First) (Middle) RTEX PHARMACEUTICALS ORATED THERN AVENUE A. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial Execution Date, (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Stock O2/01/2022 A. 9,800(1) A. \$0.0 Stock O2/01/2022 A. 9,800(1) A. \$0.0 Stock O2/01/2022 A. 9,800(1) A. \$0.0 Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficial (e.g., puts, calls, warrants, options, convertible securities) Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficial (e.g., puts, calls, warrants, options, convertible securities) Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficial (e.g., puts, calls, warrants, options, convertible securities) A. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) A. \$0.0 A	(First) (Middle) RTEX PHARMACEUTICALS PORATED N MA 02210 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owner Report Transaction (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Obte (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Date (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Oate (e.g., puts, calls, warrants, options, convertible securities) 4. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) 2. Transaction Oate (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Oate (e.g., puts, calls, warrants, options, convertible securities) 4. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Oate (e.g., puts, calls, warrants, options, convertible securities) 4. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) 4. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertib	(First) (Middle) RTEX PHARMACEUTICALS ORATED THERN AVENUE A. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Date Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Y	(First) (Middle) RTEX PHARMACEUTICALS OVERATED THERN AVENUE 3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year) (Month/Day/Year) Stock 02/01/2022 A 1 9,800(1) A \$0.00 41,728 Stock 02/01/2022 A 9,800(1) A \$0.00 53,356 Stock 12-Oversion (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year) (Month/Day/Year) A 9,800(1) A \$0.00 41,728 Stock 12-Oversion (Month/Day/Year) A 11,628(2) A \$0.00 53,356 Stock 12-Oversion (Month/Day/Year) A 2-Oversion (Month/Day/Year) A 2-Oversion (Month/Day/Year) A 3-Oversion (Month/Day/Year) A 4-Oversion (Month/Day/Year) A 4-Oversion (Month/Day/Year) A 4-Ove	MA VRTX

Explanation of Responses:

- 1. Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on $\frac{02}{01}/2022$ and the shares will vest on $\frac{02}{24}/2022$.
- 2. Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
- 3. Restricted stock unit award that vests in installments beginning on 02/24/2023.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Sabrina Yohai, Attorney-in-02/03/2022 **Fact**

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Joy Liu, Sabrina Yohai, Omar White, and Christiana Stevenson of Vertex Pharmaceuticals Incorporated (the "Company"), signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, forms and authentication documents for EDGAR Filing Access;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;
- 3. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 4. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- 5. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of or transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

This Power of Attorney is intended to constitute a "confirming statement" for presentation to the Securities and Exchange Commission as contemplated by Instruction 7(a) of Forms 3, 4 and 5.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 18th day of January, 2022.

/s/ Amit Sachdev Signature

Amit Sachdev Print Name